Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm repeat-dose study of maribavir for CMV infection in pediatric and adolescent HSCT or SOT recipients
MOH_2022-07-14_011913Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of maribavir in cytomegalovirus disease (CMV) (3 cohorts), sponsored by Takeda. Primary endpoints: Pharmacokinetics of maribavir, Pediatric dose regimen identification and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on MOH_2022-07-14_011913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-14_011913.